ARKW vs XBI
ARK Next Generation Internet ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.76% for ARKW.
- • ARKW pays a higher dividend yield (1.60%).
Side-by-side metrics
| Metric | ARKW | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.76% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.60% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $1.68B | $10.92B |
YTD return | -2.91% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.36 | 1.01 |
P/E ratio | 32.79 | — |
Last price | $147.14 | $156.41 |
Inception | — | — |
Issuer | ARK | State Street |
ARKW top holdings
| TSLA | Tesla Inc | 8.49% |
| META | Meta Platforms Inc Class A | 5.12% |
| CRCL | Circle Internet Group Inc Ordinary Shares - Class A | 4.54% |
| AMZN | Amazon.com Inc | 4.42% |
| SHOP | Shopify Inc Registered Shs -A- Subord Vtg | 4.38% |
| NVDA | NVIDIA Corp | 4.19% |
| HOOD | Robinhood Markets Inc Class A | 3.73% |
| CRWV | CoreWeave Inc Ordinary Shares - Class A | 3.68% |
| SPCX | Space Exploration Technologies Corp Class A | 3.68% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About ARKW
ARKW (ARK Next Generation Internet ETF) is Active strategy targeting next-gen internet companies. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.76%, a dividend yield of 1.60%. Its largest holding is Tesla Inc (TSLA), which represents 8.5% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 17.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.